Local Drug Delivery for Coronary Artery Disease Established and Emerging Applications 1st Edition by Edoardo Camenzind, Ivan De Scheerder 9781841840451 1841840459

Local Drug Delivery for Coronary Artery Disease Established and Emerging Applications 1st Edition by Edoardo Camenzind, Ivan De Scheerder – Ebook PDF Instant Download/Delivery: 9781841840451, 1841840459

Full download Local Drug Delivery for Coronary Artery Disease Established and Emerging Applications 1st Edition after payment

 

Product details:

ISBN 10: 1841840459

ISBN 13: 9781841840451

Author: Edoardo Camenzind, Ivan De Scheerder

Pioneers in the field, the editors have assembled an excellent team of contributors with extensive experience of threatened vessel closure and restenosis, acute thrombosis, hyperproliferative cellular response, stents and local drug delivery. Comprehensive and up-to-date, this reference provides fully up-to-date information on currently available methods of drug delivery, as well as illustrations of drug delivery methods with seventy-five color and seventy-five black and white photos throughout the book. With this impressive presentation of the most up-to-date methods and applications, as well as a range of photographs illustrating their implementation, this guide is an excellent resource for cardiologists, pharmacologists, cardiac surgeons, and trainees.

Table of contents:

1 The purpose of site-specific therapy

2 Local drug delivery: impact of pressure,substance characteristics, and stenting on drug transfer into the arterial wall

3 Catheter-based and stent-based treatment for coronary artery disease

4 The ClearWay™ microporous balloon catheter

5 The Dispatch® coronary infusion catheter

6 The Remedy™ PTCA dilatation infusion catheter

7 The Infiltrator™ angioplasty balloon catheter

8 The Infiltrator™ local drug delivery catheter

9 The needle catheter

10 Stent-mediated local drug delivery

11 Silicon carbide-coated stents

12 The Carbostent: a Carbofilm™-coated stent

13 The PC-coated BiodivYsio™ stent

14 PTFE-covered stents

15 Overview of drug delivery coatings

16 Phosphorylcholine (PC Technology™) coated stents as a drug delivery platform

17 Direct stent coating: an alternative for polymers?

18 Radioactive stents

19 Overview of potential drugs to inhibit in-stent restenosis

20 Direct antithrombins

21 Tissue factor inhibitors

22 Nitric oxide-related interventions and restenosis

23 Vitamin E and its multiple properties: anti, pro, and non-oxidative activities

24 The dexamethasone eluting stent

25 Antiinflammatory approaches to restenosis

26 The role of matrix metalloproteinase inhibitors after arterial injury

27 Methotrexate: a potential drug for stent-mediated local drug delivery: antiinflammatory and antiproliferative characteristics

28 Actin-skeleton inhibitors: potential candidates for local drug delivery in the prevention of in-stent restenosis?

29 Local delivery of antisense oligomers to c-myc for the prevention of restenosis

30 Site-specific delivery of cytostatic agents

31 Catheter-based delivery of NOS gene

32 Carbon-coated stents: diamond-like stent coatings

33 Long-term biocompatibility evaluation of poly-bis-trifluorethoxyphosphazene (PTFEP): a novel biodegradable polymer stent coating in a porcine coronary stent model

34 Biocompatibility evaluation of biosoluble stent coatings in a porcine coronary stent model

35 Glycoprotein (GP) IIb/IIIa receptor antagonist eluting stents

36 Activated protein C eluting stents

37 Local methylprednisolone (MP) delivery using a BiodivYsio phosphorylcholine (PC)-coated drug delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model

38 Methotrexate-loaded BOBSC-coated coronary stents reduce neointimal hyperplasia in a porcine coronary model

39 Rapamycin eluting stents

40 Preclinical evaluation of tacrolimus-coated coronary stents

41 Local delivery of paclitaxel as a stent coating

42 Addition of cytochalasin D to a biodegradable oil stent coating inhibits intimal hyperplasia in a porcine coronary model

43 Vascular endothelial growth factor (VEGF) eluting stents

44 An advanced antisense for local vascular delivery for prevention of restenosis

45 Stent-based gene delivery

46 Catheter-based local heparin delivery

47 Local delivery of low molecular weight heparins

48 Local delivery of steroids before coronary stent implantation

49 Clinical studies with the Carbostent

50 Gold-coated stents

51 Heparin-coated stent trials

52 The Blue Medical 50% TEMPO coronary stent: preclinical studies and the first clinical pilot trial

53Dexamethasone: mode of action, preclinical, and clinical studies Ivan De Scheerder, Xiaoshun Liu, Yanming Huang, and Eric Verbeken

54 17ß-Estradiol eluting stents: a potential therapy in the prevention of restenosis

55 Batimastat: mode of action, preclinical, and clinical studies

56 The FIM trial: sirolimus eluting stents

57 Tacrolimus eluting stents

58 Everolimus eluting stents

59The Quanam drug eluting stent and the

60 The Boston Scientific paclitaxel eluting stent: TAXUS I and II

61 Clinical results with non-polymer based taxol eluting stents. The European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial

62 Intrapericardial drug delivery for the prevention of restenosis

63 Alternatives to drug eluting stents: safety and efficacy of systemic delivery of antiproliferative therapy to reduce in-stent neointimal hyperplasia

64 Drug eluting stents: a critical perspective1

People also search:

coronary artery disease drugs

coronary artery disease drug of choice

coronary artery disease medicines

coronary drug project

what drugs are used for coronary artery disease

Tags: Edoardo Camenzind, Ivan De Scheerder, Local, Delivery